Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
24 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01188408 | Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01832974 | Possible New Therapy for Advanced Cancer | terminated | Phase 1 | 9 | INSYS Therapeutics IncINDUSTRY | 1 | Apr 27, 2015 | clinicaltrials |
| NCT00024570 |
| Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma |
| completed |
| Phase 1 / Phase 2 |
| 60 |
| INSYS Therapeutics IncINDUSTRY |
| 1 |
| Nov 14, 2014 |
| clinicaltrials |
| NCT00024674 | Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days | withdrawn | Phase 1 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00024687 | Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses | withdrawn | Phase 1 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00378235 | Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00538850 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | completed | Phase 3 | 130 | INSYS Therapeutics IncINDUSTRY | 1 | Mar 5, 2014 | clinicaltrials |
| NCT00538863 | Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain | completed | Phase 3 | 319 | INSYS Therapeutics IncINDUSTRY | 3 | Oct 11, 2013 | clinicaltrials |
| NCT00956254 | Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis | completed | Phase 3 | 18 | INSYS Therapeutics IncINDUSTRY | 1 | Sep 5, 2013 | clinicaltrials |
| NCT01186731 | Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Sep 12, 2012 | clinicaltrials |
| NCT01190982 | Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer | completed | Phase 2 | 70 | INSYS Therapeutics IncINDUSTRY | 1 | Aug 24, 2012 | clinicaltrials |
| NCT00046540 | Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00080418 | Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00089427 | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 24 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00100139 | Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer | completed | Phase 1 | 48 | INSYS Therapeutics IncINDUSTRY | 3 | Jul 4, 2011 | clinicaltrials |
| NCT00100672 | Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT01151384 | Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors(LE-DT) | completed | Phase 1 | 30 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00024492 | Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00024557 | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00041587 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 80 | INSYS Therapeutics IncINDUSTRY | 3 | Jun 6, 2011 | clinicaltrials |
| NCT00064779 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 18 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00076986 | The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 3 | 300 | INSYS Therapeutics IncINDUSTRY | 6 | Jun 6, 2011 | clinicaltrials |
| NCT00024648 | Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies | completed | Phase 1 | 25 | INSYS Therapeutics IncINDUSTRY | 1 | Apr 13, 2011 | clinicaltrials |
| NCT00024661 | Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | INSYS Therapeutics IncINDUSTRY | 1 | Apr 13, 2011 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials